Lemtrada and Gilenya drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Lemtrada (alemtuzumab) and Gilenya (fingolimod). Common drug interactions include restlessness among females and balance disorder among males.
The phase IV clinical study analyzes what interactions people have when they take Lemtrada and Gilenya. It is created by eHealthMe based on reports of 130 people who take the same drugs from the FDA, and is updated regularly.
What is Lemtrada?
Lemtrada has active ingredients of alemtuzumab. eHealthMe is studying from 8,317 Lemtrada users. Check the latest studies of Lemtrada.
What is Gilenya?
Gilenya has active ingredients of fingolimod. It is often used in multiple sclerosis. eHealthMe is studying from 111,893 Gilenya users. Check the latest studies of Gilenya.
130 people who take Lemtrada and Gilenya together, and have interactions are studied.
What are the common drug interactions of Lemtrada and Gilenya, by gender? *
What are the common drug interactions of Lemtrada and Gilenya, by age (0-1 to 60+)? *
What are the existing conditions these people have? *
* Approximation only. Some reports may have incomplete information.
Do you take Lemtrada and Gilenya?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
Browse all drug interactions of Lemtrada and Gilenya:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Lemtrada:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Gilenya:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Lemtrada and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Gilenya and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zRelated publications that referenced our studies
- Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
- Alroughani R, "Fingolimod-associated amenorrhea: a report of three cases", Multiple Sclerosis Journal, 2014 Jan .
- Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
- Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
- Alroughani R, "Fingolimod-associated amenorrhea: a report of three cases", Multiple Sclerosis Journal, 2014 Jan .
- Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
How the study uses the data?
The study uses data from the FDA. It is based on alemtuzumab and fingolimod (the active ingredients of Lemtrada and Gilenya, respectively), and Lemtrada and Gilenya (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Hydrocortisone cause Cardiac Tamponade? - 5 seconds ago
- Could Hydrocortisone Sodium Succinate cause Muscle Spasms? - 10 seconds ago
- Could Verapamil Hydrochloride cause Heart Rate Decreased? - 11 seconds ago
- Could Darunavir cause Abortion? - 14 seconds ago
- Could Darunavir Ethanolate cause Asthma? - 17 seconds ago
- Weight Loss and Joint Pain - 19 seconds ago
- Could Phenergan cause Electrocardiogram Qrs Complex Abnormal? - 24 seconds ago
- Could Rubraca cause Diarrhea? - 48 seconds ago
- Could Rubraca cause Stools - Watery? - 48 seconds ago
- Could Ventolin cause Dyspnea Paroxysmal Nocturnal? - 53 seconds ago